Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Three Rivers Buys China Rights to Infergen

publication date: Oct 3, 2008

Three Rivers Pharmaceuticals, a privately held firm based in Pennsylvania, obtained the right to sell Infergen in China, beginning March 31, 2009. Infergen, also known as consensus interferon, is a bio-optimized, selective and potent type 1 interferon alpha indicated for patients with chronic hepatitis C. Financial details of the deal were not disclosed. In December 2007, Three Rivers paid $91.3 million to buy the US and Canadian rights to Infergen from Valeant. Infergen was developed by Amgen and approved by the FDA in 1997. More details...

Stock Symbols: (NYSE: VRX) (NSDQ: AMGN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here